Ethnobotanical investigation on medicinal plants in Algoz area (South Kordofan), Sudan

Autor: Tahani Osman Issa, Yahya Sulieman Mohamed, Sakina Yagi, Reem Hassan Ahmed, Telal Mohammed Najeeb, Abdelrafie Mohamed Makhawi, Tarig Osman Khider

Publikováno v: Journal of Ethnobiology and Ethnomedicine, Vol 14, Iss 1, Pp 1-22 (2018)

Abstract Background The inhabitants of western Sudan use traditional medicine for the treatment of various ailments due to lack of medical doctors and unaffordable prices of pharmaceutical products. The present study is the first documentation of the

Externí odkaz: https://doaj.org/article/fdd48f2f0a0a446bad955596335769dd

Effect of Raphanus sativus on Glucose, Cholesterol and Triglycerides Levels in Glucose Loaded Rats

Autor: Rehab Omer Elnour, Omar Musa EzzEldin, Abdalbasit Adam Mariod, Reem Hassan Ahmed, Ahlam Salih Eltahir

Publikováno v: Functional Foods in Health and Disease. 12:134

Background: In fact, diabetes is now a serious health concern, and the import of medications from other countries consumes a significant amount of foreign cash each year. The effects of Raphanus satives (Radish) in the treatment of diabetes mellitus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4e56affbd5b3e6b67b2002bd427f0e93
https://doi.org/10.31989/ffhd.v12i3.883

A Review on the Taxonomy, Ethnobotany, Phytochemistry and Pharmacology of Guriea senegalensis J.F.Gmel. (Combretaceae)

Autor: Hassan Elsafi, Eltayeb Fadul, Ahmed Saeed, Reem Hassan Ahmed, Mubarak Siddig Hamad

Publikováno v: Medicinal & Aromatic Plants.

The strong enhancement of the reflection back to the sharp (R 2 up to 50!) uniquely enables apertureless shear force SNOM, local Raman, and fluorescence of flat or rough daily life and real world surfaces of all types, including biological/medical on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2724c4bf4514a6f618cb6a03faac54b9
https://doi.org/10.4172/2155-9821.1000296

Role of insertion sequence Aba-1 and AdeS in reduced tigecycline susceptibility in MDR-Acinetobacter baumannii clinical isolates from Cairo, Egypt.

Autor: Hassan, Reem, Mukhtar, Ahmed, Hasanin, Ahmed, Ghaith, Doaa

Publikováno v: Journal of Chemotherapy (Taylor & Francis Ltd); Apr2018, Vol. 30 Issue 2, p89-94, 6p

Antitumor treatment based on the expression of NIS protein: Analysis of the tumor microenvironment in an in vitro model

Autor: Castillo-Rivera, Fabio

Publikováno v: Dohan O, Baloch Z, Banrevi Z, Livolsi V, Carrasco N. Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases. The Journal of clinical endocrinology and metabolism. 2001;86(6):2697-700. Epub 2001/06/09.
Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996;379(6564):458-60. Epub 1996/02/01.
Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, et al. Cloning of the human sodium lodide symporter. Biochemical and biophysical research communications. 1996;226(2):339-45. Epub 1996/09/13.
Perron B, Rodriguez AM, Leblanc G, Pourcher T. Cloning of the mouse sodium iodide symporter and its expression in the mammary gland and other tissues. The Journal of endocrinology. 2001;170(1):185-96. Epub 2001/06/30.
Ravera S, Reyna-Neyra A, Ferrandino G, Amzel LM, Carrasco N. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications. Annual review of physiology. 2017;79:261-89. Epub 2017/02/14.
Darrouzet E, Lindenthal S, Marcellin D, Pellequer JL, Pourcher T. The sodium/iodide symporter: state of the art of its molecular characterization. Biochimica et biophysica acta. 2014;1838(1 Pt B):244-53. Epub 2013/08/31.
Portulano C, Paroder-Belenitsky M, Carrasco N. The Na+/I-symporter (NIS): mechanism and medical impact. Endocrine reviews. 2014;35(1):106-49. Epub 2013/12/07.
Choudhury PS, Gupta M. Differentiated thyroid cancer theranostics: radioiodine and beyond. The British journal of radiology. 2018;91(1091):20180136. Epub 2018/09/28.
Martin M, Modenutti CP, Peyret V, Geysels RC, Darrouzet E, Pourcher T, et al. A Carboxy-Terminal Monoleucine-Based Motif Participates in the Basolateral Targeting of the Na+/I-Symporter. Endocrinology. 2019;160(1):156-68. Epub 2018/11/30.
Yin HY, Zhou X, Wu HF, Li B, Zhang YF. Baculovirus vector-mediated transfer of NIS gene into colon tumor cells for radionuclide therapy. World journal of gastroenterology. 2010;16(42):5367-74. Epub 2010/11/13.
Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nature medicine. 2000;6(8):871-8. Epub 2000/08/10.
Honour AJ, Myant NB, Rowlands EN. Secretion of radioiodine in digestive juices and milk in man. Clinical science. 1952;11(4):449-62. Epub 1952/11/01.
Kilbane MT, Ajjan RA, Weetman AP, Dwyer R, McDermott EW, O'Higgins NJ, et al. Tissue iodine content and serum-mediated 125I uptake-blocking activity in breast cancer. The Journal of clinical endocrinology and metabolism. 2000;85(3):1245-50. Epub 2000/03/17
Cho JY, Leveille R, Kao R, Rousset B, Parlow AF, Burak WE, Jr., et al. Hormonal regulation of radioiodide uptake activity and Na+/I-symporter expression in mammary glands. The Journal of clinical endocrinology and metabolism. 2000;85(8):2936-43. Epub 2000/08/18.
Dong L, Lu J, Zhao B, Wang W, Zhao Y. Review of the possible association between thyroid and breast carcinoma. World journal of surgical oncology. 2018;16(1):130. Epub 2018/07/07.
Poole VL, McCabe CJ. Iodide transport and breast cancer. The Journal of endocrinology. 2015;227(1):R1-R12. Epub 2015/08/20.
Elliyanti A, Putra AE, Sribudiani Y, Noormartany N, Masjhur JS, Achmad TH, et al. Epidermal Growth Factor and Adenosine Triphosphate Induce Natrium Iodide Symporter Expression in Breast Cancer Cell Lines. Open access Macedonian journal of medical sciences. 2019;7(13):2088-92. Epub 2019/08/29.
Carvalho DP, Ferreira AC. The importance of sodium/iodide symporter (NIS) for thyroid cancer management. Arquivos brasileiros de endocrinologia e metabologia. 2007;51(5):672-82. Epub 2007/09/25.
Dohan O, Carrasco N. Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyond. Molecular and cellular endocrinology. 2003;213(1):59-70. Epub 2004/04/06.
Kim SH, Chung HK, Kang JH, Kim KI, Jeon YH, Jin YN, et al. Tumor-targeted radionuclide imaging and therapy based on human sodium iodide symporter gene driven by a modified telomerase reverse transcriptase promoter. Human gene therapy. 2008;19(9):951-7. Epub 2008/09/24.
Liu RS, Hsieh YJ, Ke CC, Chen FD, Hwu L, Wang FH, et al. Specific activation of sodium iodide symporter gene in hepatoma using alpha-fetoprotein promoter combined with hepatitis B virus enhancer (EIIAPA). Anticancer research. 2009;29(1):211-21. Epub 2009/04/01.
Barton KN, Stricker H, Brown SL, Elshaikh M, Aref I, Lu M, et al. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Molecular therapy : the journal of the American Society of Gene Therapy. 2008;16(10):1761-9. Epub 2008/08/21.
Hart IR. Tissue specific promoters in targeting systemically delivered gene therapy. Seminars in oncology. 1996;23(1):154-8. Epub 1996/02/01.
Lindencrona U, Nilsson M, Forssell-Aronsson E. Similarities and differences between free 211At and 125I-transport in porcine thyroid epithelial cells cultured in bicameral chambers. Nuclear medicine and biology. 2001;28(1):41-50. Epub 2001/02/22.
Van Sande J, Massart C, Beauwens R, Schoutens A, Costagliola S, Dumont JE, et al. Anion selectivity by the sodium iodide symporter. Endocrinology. 2003;144(1):247-52. Epub 2002/12/19.
Dadachova E, Bouzahzah B, Zuckier LS, Pestell RG. Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nuclear medicine and biology. 2002;29(1):13-8. Epub 2002/01/12.
Hingorani M, Spitzweg C, Vassaux G, Newbold K, Melcher A, Pandha H, et al. The biology of the sodium iodide symporter and its potential for targeted gene delivery. Current cancer drug targets. 2010;10(2):242-67. Epub 2010/03/06.
Son SH, Gangadaran P, Ahn BC. A novel strategy of transferring NIS protein to cells using extracellular vesicles leads to increase in iodine uptake and cytotoxicity. International journal of nanomedicine. 2019;14:1779-87. Epub 2019/03/19.
Coller HA, Sang L, Roberts JM. A new description of cellular quiescence. PLoS biology. 2006;4(3):e83. Epub 2006/03/03.
Kyle AH, Baker JH, Minchinton AI. Targeting quiescent tumor cells via oxygen and IGF-I supplementation. Cancer research. 2012;72(3):801-9. Epub 2011/12/14.
Cheung TH, Rando TA. Molecular regulation of stem cell quiescence. Nature reviews Molecular cell biology. 2013;14(6):329-40. Epub 2013/05/24.
Zhang X, de Milito A, Olofsson MH, Gullbo J, D'Arcy P, Linder S. Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors. International journal of molecular sciences. 2015;16(11):27313-26. Epub 2015/11/19.
Brown J. Extra-thyroidal iodide metabolism in the rat. Endocrinology. 1956;58(1):68-78. Epub 1956/01/01.
Denef JF, Bjorkman U, Ekholm R. Structural and functional characteristics of isolated thyroid follicles. Journal of ultrastructure research. 1980;71(2):185-202. Epub 1980/05/01.
Utiger RD. Therapy of hypothyroidism--when are changes needed? The New England journal of medicine. 1990;323(2):126-7. Epub 1990/07/12.
Eskandari S, Loo DD, Dai G, Levy O, Wright EM, Carrasco N. Thyroid Na+/I-symporter. Mechanism, stoichiometry, and specificity. The Journal of biological chemistry. 1997;272(43):27230-8. Epub 1997/10/27.
Watabe T, Kaneda-Nakashima K, Liu Y, Shirakami Y, Ooe K, Toyoshima A, et al. Enhancement of (211)At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted alpha-Therapy of Thyroid Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019;60(9):1301-7. Epub 2019/02/24.
Barton MB, Frommer M, Shafiq J. Role of radiotherapy in cancer control in low-income and middle-income countries. The Lancet Oncology. 2006;7(7):584-95. Epub 2006/07/04.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69-90. Epub 2011/02/08.
Bonnema SJ, Hegedus L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocrine reviews. 2012;33(6):920-80. Epub 2012/09/11
Reiners C, Hanscheid H, Luster M, Lassmann M, Verburg FA. Radioiodine for remnant ablation and therapy of metastatic disease. Nature reviews Endocrinology. 2011;7(10):589-95. Epub 2011/08/10
Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature reviews Cancer. 2006;6(4):292-306. Epub 2006/03/25.
Chung JK, Cheon GJ. Radioiodine therapy in differentiated thyroid cancer: the first targeted therapy in oncology. Endocrinol Metab (Seoul). 2014;29(3):233-9. Epub 2014/10/14.
Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nature reviews Cancer. 2013;13(3):184-99. Epub 2013/02/23.
Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. The Journal of clinical endocrinology and metabolism. 2006;91(8):2892-9. Epub 2006/05/11.
Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. The Journal of clinical endocrinology and metabolism. 2001;86(4):1447-63. Epub 2001/04/12.
Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103(7):1330-5. Epub 2005/03/02.
Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, et al. Na+/I-symporter distribution in human thyroid tissues: an immunohistochemical study. The Journal of clinical endocrinology and metabolism. 1998;83(11):4102-6. Epub 1998/11/14.
Jhiang SM, Cho JY, Ryu KY, DeYoung BR, Smanik PA, McGaughy VR, et al. An immunohistochemical study of Na+/I-symporter in human thyroid tissues and salivary gland tissues. Endocrinology. 1998;139(10):4416-9. Epub 1998/09/29.
Castro MR, Bergert ER, Beito TG, Roche PC, Ziesmer SC, Jhiang SM, et al. Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer. The Journal of endocrinology. 1999;163(3):495-504. Epub 1999/12/10.
Jung MY, Offord CP, Ennis MK, Kemler I, Neuhauser C, Dingli D. In Vivo Estimation of Oncolytic Virus Populations within Tumors. Cancer research. 2018;78(20):5992-6000. Epub 2018/08/18.
Warner SG, Kim SI, Chaurasiya S, O'Leary MP, Lu J, Sivanandam V, et al. A Novel Chimeric Poxvirus Encoding hNIS Is Tumor-Tropic, Imageable, and Synergistic with Radioiodine to Sustain Colon Cancer Regression. Molecular therapy oncolytics. 2019;13:82-92. Epub 2019/05/08
Msaouel P, Opyrchal M, Dispenzieri A, Peng KW, Federspiel MJ, Russell SJ, et al. Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Current cancer drug targets. 2018;18(2):177-87. Epub 2017/02/24.
Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nature clinical practice Endocrinology & metabolism. 2007;3(3):260-9. Epub 2007/02/23.
Kim YH, Youn H, Na J, Hong KJ, Kang KW, Lee DS, et al. Codon-optimized human sodium iodide symporter (opt-hNIS) as a sensitive reporter and efficient therapeutic gene. Theranostics. 2015;5(1):86-96. Epub 2015/01/02.
Kogai T, Brent GA. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacology & therapeutics. 2012;135(3):355-70. Epub 2012/07/04.
Liu J, Liu Y, Lin Y, Liang J. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy. Endocrinol Metab (Seoul). 2019;34(3):215-25. Epub 2019/10/01.
Aashiq M, Silverman DA, Na'ara S, Takahashi H, Amit M. Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies. Cancers. 2019;11(9). Epub 2019/09/20.
Russo D, Damante G, Puxeddu E, Durante C, Filetti S. Epigenetics of thyroid cancer and novel therapeutic targets. Journal of molecular endocrinology. 2011;46(3):R73-81. Epub 2011/02/18
Smith VE, Sharma N, Watkins RJ, Read ML, Ryan GA, Kwan PP, et al. Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors. The Journal of clinical endocrinology and metabolism. 2013;98(7):2876-86. Epub 2013/05/17.
Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. The New England journal of medicine. 2013;368(7):623-32. Epub 2013/02/15.
Feng F, Yehia L, Ni Y, Chang YS, Jhiang SM, Eng C. A Nonpump Function of Sodium Iodide Symporter in Thyroid Cancer via Cross-talk with PTEN Signaling. Cancer research. 2018;78(21):6121-33. Epub 2018/09/16.
Feng F, Yehia L, Eng C. Pro-tumorigenic non-pump function of sodium iodide symporter: A reimagined Trojan horse? Oncotarget. 2019;10(7):688-9. Epub 2019/02/19.
Ribeiro Franco PI, Rodrigues AP, de Menezes LB, Pacheco Miguel M. Tumor microenvironment components: Allies of cancer progression. Pathology, research and practice. 2020;216(1):152729. Epub 2019/11/19.
Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nature medicine. 2011;17(11):1359-70. Epub 2011/11/09.
de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nature reviews Cancer. 2006;6(1):24-37. Epub 2006/01/07.
Kalluri R, Zeisberg M. Fibroblasts in cancer. Nature reviews Cancer. 2006;6(5):392-401. Epub 2006/03/31.
Ohlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. The Journal of experimental medicine. 2017;214(3):579-96. Epub 2017/02/25.
Jena MK, Janjanam J. Role of extracellular matrix in breast cancer development: a brief update. F1000Research. 2018;7:274. Epub 2018/07/12.
Correa LH, Correa R, Farinasso CM, de Sant'Ana Dourado LP, Magalhaes KG. Adipocytes and Macrophages Interplay in the Orchestration of Tumor Microenvironment: New Implications in Cancer Progression. Frontiers in immunology. 2017;8:1129. Epub 2017/10/04.
Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. The Journal of cell biology. 2012;196(4):395-406. Epub 2012/02/22.
Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annual review of cell and developmental biology. 2007;23:675-99. Epub 2007/07/25
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(7):3983-8. Epub 2003/03/12.
Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741-51. Epub 2010/06/10
Aponte PM, Caicedo A. Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment. Stem cells international. 2017;2017:5619472. Epub 2017/05/06.
Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(33):13820-5. Epub 2009/08/12.
Cheung TH, Quach NL, Charville GW, Liu L, Park L, Edalati A, et al. Maintenance of muscle stem-cell quiescence by microRNA-489. Nature. 2012;482(7386):524-8. Epub 2012/02/24.
Arnold CP, Tan R, Zhou B, Yue SB, Schaffert S, Biggs JR, et al. MicroRNA programs in normal and aberrant stem and progenitor cells. Genome research. 2011;21(5):798-810. Epub 2011/04/01.
La T, Liu GZ, Farrelly M, Cole N, Feng YC, Zhang YY, et al. A p53-Responsive miRNA Network Promotes Cancer Cell Quiescence. Cancer research. 2018;78(23):6666-79. Epub 2018/10/12.
Zalatnai A. Molecular aspects of stromal-parenchymal interactions in malignant neoplasms. Current molecular medicine. 2006;6(6):685-93. Epub 2006/10/07.
Laconi E. The evolving concept of tumor microenvironments. BioEssays : news and reviews in molecular, cellular and developmental biology. 2007;29(8):738-44. Epub 2007/07/11.
Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer research. 2012;72(19):4875-82. Epub 2012/09/25.
Justus CR, Sanderlin EJ, Yang LV. Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment. International journal of molecular sciences. 2015;16(5):11055-86. Epub 2015/05/20.
Huang Y, Lin D, Taniguchi CM. Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe? Science China Life sciences. 2017;60(10):1114-24. Epub 2017/10/19.
Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L, Landi S. Targeting hypoxic response for cancer therapy. Oncotarget. 2016;7(12):13464-78. Epub 2016/02/10.
Lendahl U, Lee KL, Yang H, Poellinger L. Generating specificity and diversity in the transcriptional response to hypoxia. Nature reviews Genetics. 2009;10(12):821-32. Epub 2009/11/04.
Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nature reviews Cancer. 2004;4(11):891-9. Epub 2004/11/02.
Silva-Filho AF, Sena WLB, Lima LRA, Carvalho LVN, Pereira MC, Santos LGS, et al. Glycobiology Modifications in Intratumoral Hypoxia: The Breathless Side of Glycans Interaction. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2017;41(5):1801-29. Epub 2017/04/05.
Warburg O. On respiratory impairment in cancer cells. Science. 1956;124(3215):269-70. Epub 1956/08/10.
Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-14. Epub 1956/02/24.
Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes & development. 2009;23(5):537-48. Epub 2009/03/10.
DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell metabolism. 2008;7(1):11-20. Epub 2008/01/08.
Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol. 2010;6(1):127-48. Epub 2009/12/22.
Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2009;92(3):329-33. Epub 2009/07/17.
Semenza GL. Tumor metabolism: cancer cells give and take lactate. The Journal of clinical investigation. 2008;118(12):3835-7. Epub 2008/11/27.
Hardee ME, Dewhirst MW, Agarwal N, Sorg BS. Novel imaging provides new insights into mechanisms of oxygen transport in tumors. Current molecular medicine. 2009;9(4):435-41. Epub 2009/06/13.
Parks SK, Chiche J, Pouyssegur J. pH control mechanisms of tumor survival and growth. Journal of cellular physiology. 2011;226(2):299-308. Epub 2010/09/22.
Odunewu A, Fliegel L. Acidosis-mediated regulation of the NHE1 isoform of the Na(+)/H(+) exchanger in renal cells. American journal of physiology Renal physiology. 2013;305(3):F370-81. Epub 2013/05/17.
Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. The Journal of biological chemistry. 2006;281(14):9030-7. Epub 2006/02/03
Sedlakova O, Svastova E, Takacova M, Kopacek J, Pastorek J, Pastorekova S. Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Frontiers in physiology. 2014;4:400. Epub 2014/01/11.
Folkerts H, Hilgendorf S, Vellenga E, Bremer E, Wiersma VR. The multifaceted role of autophagy in cancer and the microenvironment. Medicinal research reviews. 2019;39(2):517-60. Epub 2018/10/12
Cho RW, Clarke MF. Recent advances in cancer stem cells. Current opinion in genetics & development. 2008;18(1):48-53. Epub 2008/03/22.
Kumari S, Badana AK, G MM, G S, Malla R. Reactive Oxygen Species: A Key Constituent in Cancer Survival. Biomarker insights. 2018;13:1177271918755391. Epub 2018/02/17
Weinberg F, Ramnath N, Nagrath D. Reactive Oxygen Species in the Tumor Microenvironment: An Overview. Cancers. 2019;11(8). Epub 2019/08/21.
Kobayashi M, Yamamoto M. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Advances in enzyme regulation. 2006;46:113-40. Epub 2006/08/05.
Lin W, Shen G, Yuan X, Jain MR, Yu S, Zhang A, et al. Regulation of Nrf2 transactivation domain activity by p160 RAC3/SRC3 and other nuclear co-regulators. Journal of biochemistry and molecular biology. 2006;39(3):304-10. Epub 2006/06/08.
Copple I.M. GCE, Kitteringham N.R., Park B.K. he Keap1-Nrf2 Cellular Defense Pathway: Mechanisms of Regulation and Role in Protection Against Drug-Induced Toxicity. Berlin, Heidelberg Springer; 2010.
McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. The Journal of biological chemistry. 2006;281(34):24756-68. Epub 2006/06/23.
Tong KI, Kobayashi A, Katsuoka F, Yamamoto M. Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. Biological chemistry. 2006;387(10-11):1311-20. Epub 2006/11/04.
Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochemical and biophysical research communications. 1997;236(2):313-22. Epub 1997/07/18.
Hagiya Y, Adachi T, Ogura S, An R, Tamura A, Nakagawa H, et al. Nrf2-dependent induction of human ABC transporter ABCG2 and heme oxygenase-1 in HepG2 cells by photoactivation of porphyrins: biochemical implications for cancer cell response to photodynamic therapy. Journal of experimental therapeutics & oncology. 2008;7(2):153-67. Epub 2008/09/06.
Chanas SA, Jiang Q, McMahon M, McWalter GK, McLellan LI, Elcombe CR, et al. Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. The Biochemical journal. 2002;365(Pt 2):405-16. Epub 2002/05/07.
Sajadimajd S, Khazaei M. Oxidative Stress and Cancer: The Role of Nrf2. Current cancer drug targets. 2018;18(6):538-57. Epub 2017/10/04.
Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nature medicine. 2017;23(11):1362-8. Epub 2017/10/03.
Lignitto L, LeBoeuf SE, Homer H, Jiang S, Askenazi M, Karakousi TR, et al. Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1. Cell. 2019;178(2):316-29 e18. Epub 2019/07/02.
eong Y, Hellyer JA, Stehr H, Hoang NT, Niu X, Das M, et al. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020;26(1):274-81. Epub 2019/09/25.
Arbour KC, Jordan E, Kim HR, Dienstag J, Yu HA, Sanchez-Vega F, et al. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018;24(2):334-40. Epub 2017/11/02.
Kitamura H, Onodera Y, Murakami S, Suzuki T, Motohashi H. IL-11 contribution to tumorigenesis in an NRF2 addiction cancer model. Oncogene. 2017;36(45):6315-24. Epub 2017/07/18.
Kitamura H, Motohashi H. NRF2 addiction in cancer cells. Cancer science. 2018;109(4):900-11. Epub 2018/02/17.
Stacy DR, Ely K, Massion PP, Yarbrough WG, Hallahan DE, Sekhar KR, et al. Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head & neck. 2006;28(9):813-8. Epub 2006/04/26
Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology. 2008;135(4):1358-68, 68 e1-4. Epub 2008/08/12.
Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(36):13568-73. Epub 2008/09/02.
Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, Lloyd B, et al. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Molecular cancer. 2011;10:37. Epub 2011/04/15.
Rodriguez AE, Ducker GS, Billingham LK, Martinez CA, Mainolfi N, Suri V, et al. Serine Metabolism Supports Macrophage IL-1beta Production. Cell metabolism. 2019;29(4):1003-11 e4. Epub 2019/02/19.
Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer cell. 2012;22(1):66-79. Epub 2012/07/14.
McDonald JT, Kim K, Norris AJ, Vlashi E, Phillips TM, Lagadec C, et al. Ionizing radiation activates the Nrf2 antioxidant response. Cancer research. 2010;70(21):8886-95. Epub 2010/10/14.
Tsukimoto M, Tamaishi N, Homma T, Kojima S. Low-dose gamma-ray irradiation induces translocation of Nrf2 into nuclear in mouse macrophage RAW264.7 cells. Journal of radiation research. 2010;51(3):349-53. Epub 2010/04/23.
Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacological research. 2008;58(5-6):262-70. Epub 2008/10/08.
Richard-Fiardo P, Franken PR, Lamit A, Marsault R, Guglielmi J, Cambien B, et al. Normalisation to blood activity is required for the accurate quantification of Na/I symporter ectopic expression by SPECT/CT in individual subjects. PloS one. 2012;7(3):e34086. Epub 2012/04/04.
Gengenbacher N, Singhal M, Augustin HG. Preclinical mouse solid tumour models: status quo, challenges and perspectives. Nature reviews Cancer. 2017;17(12):751-65. Epub 2017/10/28.
Sabit H, Samy MB, Said OA, El-Zawahri MM. Procaine Induces Epigenetic Changes in HCT116 Colon Cancer Cells. Genetics research international. 2016;2016:8348450. Epub 2016/11/16.
Dayem M, Basquin C, Navarro V, Carrier P, Marsault R, Chang P, et al. Comparison of expressed human and mouse sodium/iodide symporters reveals differences in transport properties and subcellular localization. The Journal of endocrinology. 2008;197(1):95-109. Epub 2008/03/29.
Kim KI, Kang JH, Chung JK, Lee YJ, Jeong JM, Lee DS, et al. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2007;48(9):1553-61. Epub 2007/08/21.
D'Ignazio L, Bandarra D, Rocha S. NF-kappaB and HIF crosstalk in immune responses. The FEBS journal. 2016;283(3):413-24. Epub 2015/10/30.
Wendland K, Thielke M, Meisel A, Mergenthaler P. Intrinsic hypoxia sensitivity of the cytomegalovirus promoter. Cell death & disease. 2015;6:e1905. Epub 2015/10/16.
Leung CO, Wong CC, Fan DN, Kai AK, Tung EK, Xu IM, et al. PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma. Oncotarget. 2015;6(13):10880-92. Epub 2015/04/03.
Li XF, Ma Y, Sun X, Humm JL, Ling CC, O'Donoghue JA. High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2010;51(4):632-8. Epub 2010/03/31.
Bedessem B, Stephanou A. A mathematical model of HiF-1alpha-mediated response to hypoxia on the G1/S transition. Mathematical biosciences. 2014;248:31-9. Epub 2013/12/19.
Park HJ, Lyons JC, Ohtsubo T, Song CW. Acidic environment causes apoptosis by increasing caspase activity. British journal of cancer. 1999;80(12):1892-7. Epub 1999/09/02.
Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Current opinion in genetics & development. 2010;20(1):51-6. Epub 2009/11/28.
Hayashi M, Sakata M, Takeda T, Yamamoto T, Okamoto Y, Sawada K, et al. Induction of glucose transporter 1 expression through hypoxia-inducible factor 1alpha under hypoxic conditions in trophoblast-derived cells. The Journal of endocrinology. 2004;183(1):145-54. Epub 2004/11/05.
Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature reviews Cancer. 2008;8(9):705-13. Epub 2009/01/15.
Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutations in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America. 1990;87(19):7555-9. Epub 1990/10/01.
Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, et al. Tumour-associated mutant p53 drives the Warburg effect. Nature communications. 2013;4:2935. Epub 2013/12/18.
Filetti S, Vetri M, Damante G, Belfiore A. Thyroid autoregulation: effect of iodine on glucose transport in cultured thyroid cells. Endocrinology. 1986;118(4):1395-400. Epub 1986/04/01.
Rehab El nour Omer, Omer Musa Izz eldin and Reem Hassan Ahmed Rehab. Effect of potassium iodide on glucose, cholesterol and triglycerides levels in glucose loaded rats. International Journal of Pharmacy and Biological Sciences. 2015;5:96-9.
Zhang Z, Deng X, Liu Y, Sun L, Chen F. PKM2, function and expression and regulation. Cell & bioscience. 2019;9:52. Epub 2019/08/09.
Mazurek S. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Foundation symposium proceedings. 2007(4):99-124. Epub 2008/09/25.
Warburg O, Wind F, Negelein E. The Metabolism of Tumors in the Body. The Journal of general physiology. 1927;8(6):519-30. Epub 1927/03/07.
Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. The Journal of biological chemistry. 2001;276(46):43407-12. Epub 2001/09/15.
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-33. Epub 2009/05/23.
Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, et al. Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro-oncology. 2014;16(5):686-95. Epub 2013/12/25.
Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. The Journal of biological chemistry. 1996;271(51):32529-37. Epub 1996/12/20.
Koukourakis MI, Giatromanolaki A, Panteliadou M, Pouliliou SE, Chondrou PS, Mavropoulou S, et al. Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy. British journal of cancer. 2014;110(9):2217-23. Epub 2014/04/10.
Marchiq I, Pouyssegur J. Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters. J Mol Med (Berl). 2016;94(2):155-71. Epub 2015/06/24.
Chen JL, Lucas JE, Schroeder T, Mori S, Wu J, Nevins J, et al. The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS genetics. 2008;4(12):e1000293. Epub 2008/12/06.
Xie J, Wu H, Dai C, Pan Q, Ding Z, Hu D, et al. Beyond Warburg effect--dual metabolic nature of cancer cells. Scientific reports. 2014;4:4927. Epub 2014/05/14.
Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1996;37(9):1468-72. Epub 1996/09/01.
Matsuzu K, Segade F, Matsuzu U, Carter A, Bowden DW, Perrier ND. Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid : official journal of the American Thyroid Association. 2004;14(10):806-12. Epub 2004/12/14.
Matsuzu K, Segade F, Wong M, Clark OH, Perrier ND, Bowden DW. Glucose transporters in the thyroid. Thyroid : official journal of the American Thyroid Association. 2005;15(6):545-50. Epub 2005/07/21.
Ruan M, Liu M, Dong Q, Chen L. Iodide-and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer. The Journal of clinical endocrinology and metabolism. 2015;100(5):1771-9. Epub 2015/03/15.
Rizwan H, Pal S, Sabnam S, Pal A. High glucose augments ROS generation regulates mitochondrial dysfunction and apoptosis via stress signalling cascades in keratinocytes. Life sciences. 2020;241:117148. Epub 2019/12/13.
Holynska-Iwan I, Wroblewski M, Olszewska-Slonina D, Tyrakowski T. [The application of N-acetylcysteine in optimization of specific pharmacological therapies]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. 2017;43(255):140-4. Epub 2017/10/08. Zastosowanie N-acetylocysteiny do optymalizacji specyficznych terapii farmakologicznych.
Serrano-Nascimento C, da Silva Teixeira S, Nicola JP, Nachbar RT, Masini-Repiso AM, Nunes MT. The acute inhibitory effect of iodide excess on sodium/iodide symporter expression and activity involves the PI3K/Akt signaling pathway. Endocrinology. 2014;155(3):1145-56. Epub 2014/01/16.
Ma Q. Role of nrf2 in oxidative stress and toxicity. Annual review of pharmacology and toxicology. 2013;53:401-26. Epub 2013/01/09.
Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P, et al. Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Molecular and cellular biology. 2001;21(10):3436-44. Epub 2001/04/21.
Shi X, Zhang Y, Zheng J, Pan J. Reactive oxygen species in cancer stem cells. Antioxidants & redox signaling. 2012;16(11):1215-28. Epub 2012/02/10.
Ammon HP, Muller PH, Eggstein M, Wintermantel C, Aigner B, Safayhi H, et al. Increase in glucose consumption by acetylcysteine during hyperglycemic clamp. A study with healthy volunteers. Arzneimittel-Forschung. 1992;42(5):642-5. Epub 1992/05/01
Falach-Malik A, Rozenfeld H, Chetboun M, Rozenberg K, Elyasiyan U, Sampson SR, et al. N-Acetyl-L-Cysteine inhibits the development of glucose intolerance and hepatic steatosis in diabetes-prone mice. American journal of translational research. 2016;8(9):3744-56. Epub 2016/10/12.
De la Vieja A, Santisteban P. Role of iodide metabolism in physiology and cancer. Endocrine-related cancer. 2018;25(4):R225-R45. Epub 2018/02/14.
Zhang L, Sharma S, Zhu LX, Kogai T, Hershman JM, Brent GA, et al. Nonradioactive iodide effectively induces apoptosis in genetically modified lung cancer cells. Cancer research. 2003;63(16):5065-72. Epub 2003/08/28.
Sarkar D, Chakraborty A, Saha A, Chandra AK. Iodine in excess in the alterations of carbohydrate and lipid metabolic pattern as well as histomorphometric changes in associated organs. Journal of basic and clinical physiology and pharmacology. 2018;29(6):631-43. Epub 2018/08/02.
Liemburg-Apers DC, Willems PH, Koopman WJ, Grefte S. Interactions between mitochondrial reactive oxygen species and cellular glucose metabolism. Archives of toxicology. 2015;89(8):1209-26. Epub 2015/06/07.
Lorenz MA, Burant CF, Kennedy RT. Reducing time and increasing sensitivity in sample preparation for adherent mammalian cell metabolomics. Analytical chemistry. 2011;83(9):3406-14. Epub 2011/04/05.
Holman JD, Tabb DL, Mallick P. Employing ProteoWizard to Convert Raw Mass Spectrometry Data. Current protocols in bioinformatics. 2014;46:13 24 1-9. Epub 2014/06/19.
Pluskal T, Castillo S, Villar-Briones A, Oresic M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC bioinformatics. 2010;11:395. Epub 2010/07/24.
Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB 3.0--The Human Metabolome Database in 2013. Nucleic acids research. 2013;41(Database issue):D801-7. Epub 2012/11/20.
Chong J, Soufan O, Li C, Caraus I, Li S, Bourque G, et al. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. Nucleic acids research. 2018;46(W1):W486-W94. Epub 2018/05/16.
Chong J, Wishart DS, Xia J. Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis. Current protocols in bioinformatics. 2019;68(1):e86. Epub 2019/11/23.
Nam SO, Yotsumoto F, Miyata K, Fukagawa S, Yamada H, Kuroki M, et al. Warburg effect regulated by amphiregulin in the development of colorectal cancer. Cancer medicine. 2015;4(4):575-87. Epub 2015/02/04.
Bosch EH, van Doorne H, de Vries S. The lactoperoxidase system: the influence of iodide and the chemical and antimicrobial stability over the period of about 18 months. Journal of applied microbiology. 2000;89(2):215-24. Epub 2000/09/06.
Huang YY, Choi H, Kushida Y, Bhayana B, Wang Y, Hamblin MR. Broad-Spectrum Antimicrobial Effects of Photocatalysis Using Titanium Dioxide Nanoparticles Are Strongly Potentiated by Addition of Potassium Iodide. Antimicrobial agents and chemotherapy. 2016;60(9):5445-53. Epub 2016/07/07.
Ihalin R, Loimaranta V, Tenovuo J. Origin, structure, and biological activities of peroxidases in human saliva. Archives of biochemistry and biophysics. 2006;445(2):261-8. Epub 2005/08/23.
Fischer AJ, Lennemann NJ, Krishnamurthy S, Pocza P, Durairaj L, Launspach JL, et al. Enhancement of respiratory mucosal antiviral defenses by the oxidation of iodide. American journal of respiratory cell and molecular biology. 2011;45(4):874-81. Epub 2011/03/29.
Soriano O, Delgado G, Anguiano B, Petrosyan P, Molina-Servin ED, Gonsebatt ME, et al. Antineoplastic effect of iodine and iodide in dimethylbenz[a]anthracene-induced mammary tumors: association between lactoperoxidase and estrogen-adduct production. Endocrine-related cancer. 2011;18(4):529-39. Epub 2011/06/22.
Rosner H, Moller W, Groebner S, Torremante P. Antiproliferative/cytotoxic effects of molecular iodine, povidone-iodine and Lugol's solution in different human carcinoma cell lines. Oncology letters. 2016;12(3):2159-62. Epub 2016/09/08.
Green WL. Further studies of the effects of inorganic iodide on thyroidal intermediary metabolism in vitro. Endocrinology. 1966;79(1):1-9. Epub 1966/07/01.
Guzy RD, Schumacker PT. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Experimental physiology. 2006;91(5):807-19. Epub 2006/07/22.
Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell metabolism. 2006;3(3):177-85. Epub 2006/03/07.
Maciewicz RA, Wotton SF, Etherington DJ, Duance VC. Susceptibility of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L. FEBS letters. 1990;269(1):189-93. Epub 1990/08/20.
Buck MR, Karustis DG, Day NA, Honn KV, Sloane BF. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. The Biochemical journal. 1992;282 ( Pt 1):273-8. Epub 1992/02/15.
Ostad M, Weiss R, Droller M, Liu B. Ha-ras oncogene induction of invasion and metastasis is associated with the activation and redistribution of protease(s) in rat-kidney cells. International journal of oncology. 1992;1(7):765-71. Epub 1992/12/01.
Park HJ, Makepeace CM, Lyons JC, Song CW. Effect of intracellular acidity and ionomycin on apoptosis in HL-60 cells. Eur J Cancer. 1996;32A(3):540-6. Epub 1996/03/01.
195. Rahmani S, Defferrari MS, Wakarchuk WW, Antonescu CN. Energetic adaptations: Metabolic control of endocytic membrane traffic. Traffic. 2019;20(12):912-31. Epub 2019/10/18.
196. Lee HJ, Jedrychowski MP, Vinayagam A, Wu N, Shyh-Chang N, Hu Y, et al. Proteomic and Metabolomic Characterization of a Mammalian Cellular Transition from Quiescence to Proliferation. Cell reports. 2017;20(3):721-36. Epub 2017/07/21.
Wapnir IL, van de Rijn M, Nowels K, Amenta PS, Walton K, Montgomery K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. The Journal of clinical endocrinology and metabolism. 2003;88(4):1880-8. Epub 2003/04/08.
Peyrottes I, Navarro V, Ondo-Mendez A, Marcellin D, Bellanger L, Marsault R, et al. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers. European journal of endocrinology. 2009;160(2):215-25. Epub 2008/11/26.
Wang Y, Ohh M. Oxygen-mediated endocytosis in cancer. Journal of cellular and molecular medicine. 2010;14(3):496-503. Epub 2010/01/20.
Dada LA, Chandel NS, Ridge KM, Pedemonte C, Bertorello AM, Sznajder JI. Hypoxia-induced endocytosis of Na,K-ATPase in alveolar epithelial cells is mediated by mitochondrial reactive oxygen species and PKC-zeta. The Journal of clinical investigation. 2003;111(7):1057-64. Epub 2003/04/03.
Dada LA, Novoa E, Lecuona E, Sun H, Sznajder JI. Role of the small GTPase RhoA in the hypoxia-induced decrease of plasma membrane Na,K-ATPase in A549 cells. Journal of cell science. 2007;120(Pt 13):2214-22. Epub 2007/06/07.
Kiang JG, Wang XD, Ding XZ, Gist ID, Smallridge RC. Heat shock inhibits the hypoxia-induced effects on iodide uptake and signal transduction and enhances cell survival in rat thyroid FRTL-5 cells. Thyroid : official journal of the American Thyroid Association. 1996;6(5):475-83. Epub 1996/10/01.
Vadysirisack DD, Chen ES, Zhang Z, Tsai MD, Chang GD, Jhiang SM. Identification of in vivo phosphorylation sites and their functional significance in the sodium iodide symporter. The Journal of biological chemistry. 2007;282(51):36820-8. Epub 2007/10/05
Chung T, Youn H, Yeom CJ, Kang KW, Chung JK. Glycosylation of Sodium/Iodide Symporter (NIS) Regulates Its Membrane Translocation and Radioiodine Uptake. PloS one. 2015;10(11):e0142984. Epub 2015/11/26.
Wang Y, Roche O, Yan MS, Finak G, Evans AJ, Metcalf JL, et al. Regulation of endocytosis via the oxygen-sensing pathway. Nature medicine. 2009;15(3):319-24. Epub 2009/03/03.
Szul T, Sztul E. COPII and COPI traffic at the ER-Golgi interface. Physiology (Bethesda). 2011;26(5):348-64. Epub 2011/10/21.
Matsuoka K, Orci L, Amherdt M, Bednarek SY, Hamamoto S, Schekman R, et al. COPII-coated vesicle formation reconstituted with purified coat proteins and chemically defined liposomes. Cell. 1998;93(2):263-75. Epub 1998/05/06.
Barroso M, Nelson DS, Sztul E. Transcytosis-associated protein (TAP)/p115 is a general fusion factor required for binding of vesicles to acceptor membranes. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(2):527-31. Epub 1995/01/17.
Royle SJ. The cellular functions of clathrin. Cellular and molecular life sciences : CMLS. 2006;63(16):1823-32. Epub 2006/05/16.
Pedersen NB, Carlsson MC, Pedersen SF. Glycosylation of solute carriers: mechanisms and functional consequences. Pflugers Archiv : European journal of physiology. 2016;468(2):159-76. Epub 2015/09/19.
Huet G, Gouyer V, Delacour D, Richet C, Zanetta JP, Delannoy P, et al. Involvement of glycosylation in the intracellular trafficking of glycoproteins in polarized epithelial cells. Biochimie. 2003;85(3-4):323-30. Epub 2003/05/29.
Levy O, Dai G, Riedel C, Ginter CS, Paul EM, Lebowitz AN, et al. Characterization of the thyroid Na+/I-symporter with an anti-COOH terminus antibody. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(11):5568-73. Epub 1997/05/27.
Zhou F, Xu W, Hong M, Pan Z, Sinko PJ, Ma J, et al. The role of N-linked glycosylation in protein folding, membrane targeting, and substrate binding of human organic anion transporter hOAT4. Molecular pharmacology. 2005;67(3):868-76. Epub 2004/12/04.
Levy O, De la Vieja A, Ginter CS, Riedel C, Dai G, Carrasco N. N-linked glycosylation of the thyroid Na+/I-symporter (NIS). Implications for its secondary structure model. The Journal of biological chemistry. 1998;273(35):22657-63. Epub 1998/08/26.
Chai W, Ye F, Zeng L, Li Y, Yang L. HMGB1-mediated autophagy regulates sodium/iodide symporter protein degradation in thyroid cancer cells. Journal of experimental & clinical cancer research : CR. 2019;38(1):325. Epub 2019/07/25.
Plantinga TS, Tesselaar MH, Morreau H, Corssmit EP, Willemsen BK, Kusters B, et al. Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer. Autophagy. 2016;12(7):1195-205. Epub 2016/04/23.
Ravanan P, Srikumar IF, Talwar P. Autophagy: The spotlight for cellular stress responses. Life sciences. 2017;188:53-67. Epub 2017/09/04.
Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S, et al. Expression of the Na+/I-symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. The Journal of clinical endocrinology and metabolism. 1999;84(9):3228-34. Epub 1999/09/16.
Xu XD, Shao SX, Jiang HP, Cao YW, Wang YH, Yang XC, et al. Warburg effect or reverse Warburg effect? A review of cancer metabolism. Oncology research and treatment. 2015;38(3):117-22. Epub 2015/03/21.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario

El co-transportador de sodio/yoduro (NIS) media la captación de yoduro en la tiroides. Desde hace décadas, la captación de yoduro mediada por NIS es una herramienta muy útil para la ablación radiactiva de las células de cáncer de tiroides. La

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3056::295bef5ecaff8f55945f223029bd2f6f
https://repository.urosario.edu.co/handle/10336/30751